SUMMARY
Glucocorticoids (GCs) are used as anti-inflammatory and immunosuppressive drugs in many immune mediated diseases, but their use in sepsis and shock is controversial. This is caused in part by a lack of information regarding the responding cell types and GC-regulated genes in vivo. We used public blood transcriptomic datasets and GC-induced query genes to obtain 2 robust gene expression correlation signatures of GC induction, either in the absence or in the presence of severe inflammation. GC signature 1 originated from circadian cortisol with biases for gene expression in NK cells and neutrophils. GC signature 2 originated from GC in severe inflammation, mainly with biases for gene expression in monocytes and neutrophils. Many genes upregulated by GC treatment in septic shock and burn shock were also present as high-ranking genes in GC signatures, which pointed to their direct regulation by GC. Robust GC signatures were also obtained from dataset collections of monocytes and neutrophils, separately, and predicted cellular effects. Additionally, gene induction by GC was put into a wider framework of gene expression in circulating monocytes and neutrophils in health and systemic inflammation. We present and interpret a large number of GC-regulated genes in different blood cells and tissues, and select 2 whole blood transcriptomic biomarker gene sets, GC-1 and GC-2, for monitoring cortisol action in health, and in severe inflammation, respectively. GC signature 2 was found in sepsis and many other inflammatory diseases, both from treatment with GC, and from endogenous GC.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/ArthurJohannes/GCblood_repo
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data located at NCBI GEO database, and at the ArrayExpress repository
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email : l.koenderman{at}umcutrecht.nl
The manuscript has been revised, now starting with 2 signatures of GC-driven gene expression in blood using defined transcriptomic dataset collections for reproducibility, instead of programmatically selected datasets from a large collection of 375+ blood transcriptomic datasets. A much larger number of candidate GC- regulated genes in whole blood, PBMCs, monocytes, neutrophils, lymphocytes, and tissues has been recovered, also using defined dataset collections. A limited number of most relevant GC-regulated genes was taken for further profiling in vitro and in vivo gene expression using different public dataset experiments, for example showing upregulated expression by GC treatment in shock, and in vitro in PBMCs by treatment with sepsis sera. A more detailed comparison was made between marker gene expression in mild inflammation and severe inflammation. Gene regulation by GC was placed in a broader framework of gene expression in monocytes and neutrophils in health, and during mild and severe inflammation. Additional examples were given for the presence of GC signature 2 (found in the presence of severe inflammation) in GC-untreated diseases. Biomarker gene sets for monitoring cellular GC action in whole blood were adjusted for use in different diseases, based on analysis of corresponding RNA-seq transcriptomic datasets. The basic findings remained the same as in the previous version.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
https://www.ncbi.nlm.nih.gov/gds
